2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management
Last Updated: Monday, August 16, 2021
This review article summarizes recent data and efforts to improve frontline and relapsed/refractory treatment strategies for DLBCL, including the use of risk-adapted therapy based on cell of origin and molecular features and immunotherapy for patients with advanced disease.
Advertisement
News & Literature Highlights